Last 12 months
Inside the activity.
0 purchase rows · 4 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 2 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 26, 2019 Filed Feb 28, 2019 21:54 UTC |
Eisenberg HillaCFO, Treasurer and Secretary
|
GrantStock Option (right to buy) · Derivative | 37,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-003333 · ownership.xml · derivative · entry 1 Eisenberg Hilla · CIK 0001712524 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,000 Underlying: Common Stock · 37,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 9,250 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:58 UTC |
Hasleton Mark DanielVP Business Development
|
GrantStock Option (right to buy) · Derivative | 22,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-003338 · ownership.xml · derivative · entry 1 Hasleton Mark Daniel · CIK 0001759581 · VP Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock · 22,500 shares Expires 2029-02-26 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 5,625 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:57 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 104,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-003337 · ownership.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 104,000 Underlying: Common Stock · 104,000 shares Expires 2029-02-26 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Feb 28, 2019 21:55 UTC |
KIDRON NADAVDirector · President and CEO · 10% owner
|
GrantStock Option (right to buy) · Derivative | 196,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-003334 · ownership.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,500 Underlying: Common Stock · 196,500 shares Expires 2029-02-26 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Sep 16, 2019 22:07 UTC |
KIDRON NADAVDirector · President and CEO · 10% owner
|
Disposition to issuerStock Option (right to buy) · Derivative | 196,500 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-018199 · ownership.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 196,500 shares Expires 2029-02-26 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 49,125 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| February 26, 2019 Filed Sep 16, 2019 22:07 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
Disposition to issuerStock Option (right to buy) · Derivative | 104,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001213900-19-018198 · ownership.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 104,000 shares Expires 2029-02-26 F1 · kind: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. F1 · derivative.exercise_date: The two reported transactions involved the cancellation of an outstanding option and the grant of a replacement option. The option was originally granted on February 26, 2019 and provides for vesting in 4 equal installments of 26,000 on each of December 31, 2019, December 31, 2020, December 31, 2021 and December 31, 2022. Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 20:32 UTC |
Friedman AviadDirector
|
PurchaseCommon Stock | 2,000 | $4.98 | $9,960.00 |
DisclosureSEC source: 0001213900-18-010829 · ownership.xml · nonDerivative · entry 2 Friedman Aviad · CIK 0001683729 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wholly-owned corporation Disclosed balance after: 12,191 Read SEC document |
| August 09, 2018 Filed Aug 13, 2018 20:32 UTC |
Friedman AviadDirector
|
PurchaseCommon Stock | 500 | $4.82 | $2,410.00 |
DisclosureSEC source: 0001213900-18-010829 · ownership.xml · nonDerivative · entry 1 Friedman Aviad · CIK 0001683729 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By wholly-owned corporation Disclosed balance after: 10,191 Read SEC document |
| July 11, 2018 Filed Jul 12, 2018 21:11 UTC |
KIDRON NADAVDirector · President and CEO · 10% owner
|
PurchaseCommon Stock | 122 | $5.92 | $722.18 |
DisclosureSEC source: 0001213900-18-009128 · ownership.xml · nonDerivative · entry 2 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,209 F1 · price: On July 12, 2018, Mr. Kidron paid to Oramed Pharmaceuticals Inc. $3.88, representing the full amount of the profit realized in connection with these short-swing transactions. Read SEC document |
| July 10, 2018 Filed Jul 12, 2018 21:11 UTC |
KIDRON NADAVDirector · President and CEO · 10% owner
|
SaleCommon Stock | 61 | $5.98 | $364.97 |
DisclosureSEC source: 0001213900-18-009128 · ownership.xml · nonDerivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 958,087 F1 · price: On July 12, 2018, Mr. Kidron paid to Oramed Pharmaceuticals Inc. $3.88, representing the full amount of the profit realized in connection with these short-swing transactions. Read SEC document |
| May 03, 2018 Filed May 7, 2018 20:51 UTC |
Hexter JoshuaChief Operating Officer
|
GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $6.70 | $0.00 |
DisclosureSEC source: 0001213900-18-005618 · f4050318hexter_oramedpharm.xml · derivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-05-03 F1 · derivative.exercise_date: The Stock Option will vest in 16 equal installments of 1,875 on the last day of each quarter commencing June 30, 2018. Read SEC document |
| April 08, 2018 Filed Apr 10, 2018 21:41 UTC |
Hexter JoshuaChief Operating Officer
|
GrantStock option (right to buy) · Derivative | 30,000 | $0.00 Strike: $7.05 | $0.00 |
DisclosureSEC source: 0001213900-18-004250 · f4040818hexter_oramedpharm.xml · derivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2028-04-08 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 7,500 on each of April 1, 2019, April 1, 2020, April 1, 2021 and April 1, 2022. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:36 UTC |
Eisenberg HillaCFO, Treasurer and Secretary
|
GrantStock Option (right to buy) · Derivative | 15,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001213900-18-001250 · f4013118eisenberg_oramed.xml · derivative · entry 1 Eisenberg Hilla · CIK 0001712524 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 3,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:34 UTC |
KIDRON NADAVDirector · President and CEO · 10% owner
|
GrantStock Option (right to buy) · Derivative | 97,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001213900-18-001247 · f4013118nkidronnadav_oramed.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 97,000 Underlying: Common Stock · 97,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 24,250 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| January 31, 2018 Filed Feb 2, 2018 22:32 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 47,000 | $0.00 Strike: $8.14 | $0.00 |
DisclosureSEC source: 0001213900-18-001245 · f4013118kidronmiriam_oramed.xml · derivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,000 Underlying: Common Stock · 47,000 shares Expires 2028-01-31 F1 · derivative.exercise_date: The Stock Option will vest in 4 equal installments of 11,750 on each of January 1, 2019, January 1, 2020, January 1, 2021 and January 1, 2022. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 20:39 UTC |
Slager David MarkDirector
|
Exercise / conversionWarrant (right to buy) · Derivative | 16,892 | $1.18 Strike: $3.77 | $19,925.80 |
DisclosureSEC source: 0001213900-17-011195 · f4103117slager_oramedpharm.xml · derivative · entry 2 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 0 Underlying: Common Stock · 16,892 shares Expires 2017-11-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F3 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| October 31, 2017 Filed Nov 1, 2017 20:39 UTC |
Slager David MarkDirector
|
Exercise / conversionCommon Stock | 16,892 | $3.77 | $63,608.52 |
DisclosureSEC source: 0001213900-17-011195 · f4103117slager_oramedpharm.xml · nonDerivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 1,316,328 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC |
Sank LeonardDirector
|
Exercise / conversionWarrant (right to buy) · Derivative | 6,373 | Not disclosed Strike: $6.00 | Not disclosed |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · derivative · entry 6 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 6,373 shares Expires 2018-02-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The shares of common stock and warrants were granted to Mr. Sank as a finder's fee in connection with a 2012 private placement of the Issuer. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC |
Sank LeonardDirector
|
Exercise / conversionWarrant (right to buy) · Derivative | 5,631 | $1.18 Strike: $6.00 | $6,642.33 |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · derivative · entry 5 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,631 shares Expires 2017-11-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F4 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC |
Sank LeonardDirector
|
Exercise / conversionCommon Stock | 6,373 | $6.00 | $38,238.00 |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · nonDerivative · entry 2 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,162 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 23, 2017 Filed Oct 25, 2017 20:35 UTC |
Sank LeonardDirector
|
Exercise / conversionCommon Stock | 5,631 | $6.00 | $33,786.00 |
DisclosureSEC source: 0001213900-17-010951 · f4102317sank_oramedpharm.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 17:56 UTC |
Slager David MarkDirector
|
Exercise / conversionWarrant (right to buy) · Derivative | 112,613 | $1.18 Strike: $3.77 | $132,838.29 |
DisclosureSEC source: 0001213900-17-008982 · f4081717slager_oramendpharm.xml · derivative · entry 2 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 0 Underlying: Common Stock · 112,613 shares Expires 2017-08-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F3 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| August 17, 2017 Filed Aug 21, 2017 17:56 UTC |
Slager David MarkDirector
|
Exercise / conversionCommon Stock | 112,613 | $3.77 | $424,055.51 |
DisclosureSEC source: 0001213900-17-008982 · f4081717slager_oramendpharm.xml · nonDerivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · By Regals Fund LP Disclosed balance after: 1,299,436 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: Mr. Slager is Managing Member of the general partner of Regals Capital Management LP ("Regals Management"). Regals Management is the investment manager of Regals Fund LP (the "Fund"). The securities reported herein are held for the account of the Fund. Pursuant to Rule 16a-1(a)(4) under the Act, Mr. Slager disclaims beneficial ownership in the securities owned by the Fund except to the extent, if any, of his pecuniary interest therein. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 20:22 UTC |
Sank LeonardDirector
|
Exercise / conversionWarrant (right to buy) · Derivative | 11,262 | $1.18 Strike: $6.00 | $13,284.66 |
DisclosureSEC source: 0001213900-17-008889 · f4081517sank_oramedpharma.xml · derivative · entry 4 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 11,262 shares Expires 2017-08-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · shares: The number of shares underlying such warrant and the applicable exercise price reflect a one-for-twelve reverse stock split effected by the issuer on January 22, 2013. F4 · price: The shares and warrants were purchased as "units" at a price per unit of $4.44 in connection with the Issuer's 2012 private placement. The consideration was allocated to the shares and warrants based on relative fair value. The value allocated to the warrants was estimated by using the Black Scholes option-pricing model. Read SEC document |
| August 15, 2017 Filed Aug 17, 2017 20:22 UTC |
Sank LeonardDirector
|
Exercise / conversionCommon Stock | 11,262 | $6.00 | $67,572.00 |
DisclosureSEC source: 0001213900-17-008889 · f4081517sank_oramedpharma.xml · nonDerivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 282,158 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 22:00 UTC |
Li XiaopengDirector
|
PurchaseCOMMON STOCK | 89,636 | $8.50 | $761,906.00 |
DisclosureSEC source: 0001213900-17-008214 · f4080217li_oramed.xml · nonDerivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,350 Read SEC document |
| August 02, 2017 Filed Aug 3, 2017 22:00 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
SaleCommon Stock | 89,636 | $8.50 | $761,906.00 |
DisclosureSEC source: 0001213900-17-008213 · f4080217kidron_oramed.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 F1 · shares: These shares were sold to Li Xiaopeng, a director of Oramed Pharmaceuticals Inc., and the reporting person used the proceeds in connection with a personal tax payment. F2 · balance_after: Consists of 75,000 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:49 UTC |
Zommer Yifat HenCFO, Treasurer and Secretary
|
GrantStock Option (right to buy) · Derivative | 20,001 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007168 · f4063017zommer_oramed.xml · derivative · entry 1 Zommer Yifat Hen · CIK 0001462892 · CFO, Treasurer and Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,001 Underlying: Common Stock · 20,001 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 6,667 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:48 UTC |
Slager David MarkDirector
|
GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007166 · f4063017slager_oramed.xml · derivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:46 UTC |
Sank LeonardDirector
|
GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007164 · f4063017sank_oramed.xml · derivative · entry 1 Sank Leonard · CIK 0001416089 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:43 UTC |
RAKIN KEVINDirector
|
GrantStock Option (right to buy) · Derivative | 56,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007162 · f4063017rakin_oramed.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,773 Underlying: Common Stock · 56,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 4 installments as follows: 15,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019, and 10,000 on December 31, 2020. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:40 UTC |
KIDRON NADAVDirector · President and CEO · 10% owner
|
GrantStock Option (right to buy) · Derivative | 147,000 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007160 · f4063017nkidron_oramed.xml · derivative · entry 1 KIDRON NADAV · CIK 0001351779 · Director · President and CEO · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 147,000 Underlying: Common Stock · 147,000 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 49,000 on each of December 31, 2017, December 31, 2018 and December 31, 2019, subject to the company share price reaching the target of $8.0, $9.5 and $12.5 per share, respectively. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:38 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
GrantStock Option (right to buy) · Derivative | 69,999 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007158 · f4063017mkidron_oramed.xml · derivative · entry 2 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,999 Underlying: Common Stock · 69,999 shares Expires 2027-06-30 F3 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 23,333 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:38 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
GrantCommon Stock | 75,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-17-007158 · f4063017mkidron_oramed.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,636 F1 · shares: The shares vest immediately. F2 · balance_after: Consists of 164,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:37 UTC |
Li XiaopengDirector
|
GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007155 · f4063017li_oramed.xml · derivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| June 30, 2017 Filed Jul 5, 2017 19:36 UTC |
Friedman AviadDirector
|
GrantStock Option (right to buy) · Derivative | 16,773 | $0.00 Strike: $7.77 | $0.00 |
DisclosureSEC source: 0001213900-17-007153 · f4063017friedman_oramed.xml · derivative · entry 1 Friedman Aviad · CIK 0001683729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,773 Underlying: Common Stock · 16,773 shares Expires 2027-06-30 F1 · derivative.exercise_date: The Stock Option will vest in 3 equal installments of 5,591 on each of December 31, 2017, December 31, 2018 and December 31, 2019. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 21:01 UTC |
Kidron MiriamDirector · Chief Scientific Officer
|
SaleCommon Stock | 52,814 | $6.33 | $334,312.62 |
DisclosureSEC source: 0001178913-17-001170 · zk1719828.xml · nonDerivative · entry 1 Kidron Miriam · CIK 0001409232 · Director · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,636 F1 · shares: These shares were sold to Li Xiapeng, a director of Oramed Pharmaceuticals Inc. F2 · balance_after: Consists of 89,636 shares of Common Stock underlying vested Restricted Stock Units that are issuable upon request. Read SEC document |
| April 19, 2017 Filed Apr 19, 2017 21:05 UTC |
Li XiaopengDirector
|
PurchaseCommon Stock | 52,814 | $6.33 | $334,312.62 |
DisclosureSEC source: 0001178913-17-001172 · zk1719829.xml · nonDerivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 116,714 Read SEC document |
| March 20, 2017 Filed Mar 21, 2017 16:09 UTC |
Law Ronald EdwardChief Strategy Officer
|
GrantStock Option (right to buy) · Derivative | 37,152 | $0.00 Strike: $6.00 | $0.00 |
DisclosureSEC source: 0001213900-17-002644 · f4032017law_oramedpharma.xml · derivative · entry 1 Law Ronald Edward · CIK 0001701348 · Chief Strategy Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,152 Underlying: Common Stock · 37,152 shares Expires 2027-03-20 F1 · derivative.exercise_date: The Stock Option shall vest in 24 consecutive equal monthly installments commencing March 31, 2017. Read SEC document |
| February 09, 2017 Filed Feb 16, 2017 20:47 UTC |
Slager David MarkDirector
|
GrantStock Option (right to buy) · Derivative | 5,697 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001213900-17-001492 · f4020917slager_oramed.xml · derivative · entry 1 Slager David Mark · CIK 0001477733 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697 Underlying: Common Stock · 5,697 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
| February 09, 2017 Filed Feb 16, 2017 20:45 UTC |
RAKIN KEVINDirector
|
GrantStock Option (right to buy) · Derivative | 5,697 | $0.00 Strike: $6.23 | $0.00 |
DisclosureSEC source: 0001213900-17-001490 · f4020917rakin_oramed.xml · derivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,697 Underlying: Common Stock · 5,697 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
| February 09, 2017 Filed Mar 2, 2017 20:06 UTC |
Li XiaopengDirector
|
GrantStock Option (right to buy) · Derivative | 12,253 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-17-001939 · f4020917li_oramed.xml · derivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,253 Underlying: Common Stock · 12,253 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
| February 09, 2017 Filed Mar 2, 2017 20:04 UTC |
Friedman AviadDirector
|
GrantStock Option (right to buy) · Derivative | 4,084 | $0.00 Strike: $1.00 | $0.00 |
DisclosureSEC source: 0001213900-17-001937 · f4020917friedman_oramed.xml · derivative · entry 1 Friedman Aviad · CIK 0001683729 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 Underlying: Common Stock · 4,084 shares Expires 2027-02-09 F1 · derivative.exercise_date: The Stock Option will vest immediately. Read SEC document |
| December 06, 2016 Filed Dec 7, 2016 16:11 UTC |
RAKIN KEVINDirector
|
GrantCommon Stock | 3,300 | $6.59 | $21,762.84 |
DisclosureSEC source: 0001213900-16-019206 · f4120516rakin_oramedpharma.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,061 F2 · price: This transaction was executed in multiple trades at prices ranging from $6.40 to $6.65. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| December 05, 2016 Filed Dec 7, 2016 16:11 UTC |
RAKIN KEVINDirector
|
GrantCommon Stock | 2,300 | $6.38 | $14,665.03 |
DisclosureSEC source: 0001213900-16-019206 · f4120516rakin_oramedpharma.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,761 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.36 to $6.39. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| December 02, 2016 Filed Dec 5, 2016 19:24 UTC |
RAKIN KEVINDirector
|
GrantCommon Stock | 7,261 | $6.21 | $45,057.41 |
DisclosureSEC source: 0001213900-16-019147 · f4120116rakin_oramed.xml · nonDerivative · entry 2 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,461 F2 · price: This transaction was executed in multiple trades at prices ranging from $6.07 to $6.30. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| December 01, 2016 Filed Dec 5, 2016 19:24 UTC |
RAKIN KEVINDirector
|
GrantCommon Stock | 2,200 | $6.08 | $13,370.94 |
DisclosureSEC source: 0001213900-16-019147 · f4120116rakin_oramed.xml · nonDerivative · entry 1 RAKIN KEVIN · CIK 0001184421 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,200 F1 · price: This transaction was executed in multiple trades at prices ranging from $6.00 to $6.15. The price reported above in Column 4 of Table I reflects the weighted average purchase price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer complete information regarding the number of shares and prices at which each of the individual transactions was effected. Read SEC document |
| November 07, 2016 Filed Nov 7, 2016 19:27 UTC |
Li XiaopengDirector
|
GrantCommon Stock | 63,900 | $7.42 | $474,138.00 |
DisclosureSEC source: 0001213900-16-018027 · f4110716xiaopeng_oramed.xml · nonDerivative · entry 1 Li Xiaopeng · CIK 0001665100 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,900 Read SEC document |
| November 01, 2016 Filed Nov 22, 2016 20:35 UTC |
Hexter JoshuaChief Operating Officer
|
GrantCommon Stock | 70,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-16-018868 · f4110116hexter_oramedpharma.xml · nonDerivative · entry 1 Hexter Joshua · CIK 0001573235 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 F1 · date: The shares vest as follows: 9,000 shares vest immediately; 1,500 shares will vest in 18 consecutive installments on the last day of each month commencing November 30, 2016; and 17,000 will vest in each of April 30, 2017 and April 30, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.